Rotavirus Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

India

Fastest Growing Country

United States

High-Risk Population

High risk for severe rotavirus disease is infants and young children, plus anyone with weakened immunity.

Key Diagnostic Method

The most widely used method of diagnosis of rotavirus infection is antigen detection in fecal specimens using one of several commercial enzyme immunoassays (EIA).

Major Risk Factor

In general, unvaccinated children are at greatest risk of infection. Children who are not vaccinated are more likely to develop rotavirus related symptoms such as diarrhea, vomiting, and dehydration.

Major gap in the market

There are no specific therapies or therapeutics available to treat rotavirus infection. Current clinical practice is limited to symptomatic management, due to the lack of targeted antiviral therapies. At present, no approved antiviral medications are available, and no specific antiviral drug is available against rotavirus infection.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Among lab tested diarrhea, reported prevalence ranges from 6 percent to 56 percent across global surveillance networks. About 40 percent of hospitalizations for acute gastroenteritis in children aged under 5 years old were attributable to rotavirus disease in EU data, and about 40 percent hospitalizations for diarrhea in under 5s globally in sentinel sites. 111 million episodes at home, 25 million outpatient visits, 2 million inpatient visits per year globally, over 600,000 deaths in older estimates. Current WHO estimates are about 128,500 deaths in under 5s.

Gender-Specific Cases of the Disease

There is a slight male predominance in diagnosed cases, but it is not consistent enough to be a biological rule. Rotavirus was detected in a higher proportion of males than females, relative risk 1.2, with male to female ratio 1.6 to 1. This agrees with finding that boys are twice as susceptible and more likely to be hospitalized. In hospital studies, men accounted for 62.06 percent of prevalence, women 37.93 percent, ratio 1.5 to 1. In a Sudanese cross-sectional study of 755 children of 121 infected with rotavirus, 79, or 65.3 percent, were male and 42, or 34.7 percent, female.

Age-Specific Cases of the Disease

Age is the strongest predictor of rotavirus disease. Almost every child is infected once before age 5. Virtually all children at least once within the first 5 years of life, with the peak incidence widely quoted as occurring between 6 and 24 months of age. In developing countries, three quarters of children acquire their first episode before 12 months, mean age 6 to 9 months.

Ethnicity-Wise Cases of the Disease

Rotavirus infects every ethnic group. Differences in diagnosed cases reflect access, crowding, vaccine uptake and blood group genetics, not ethnicity specific immunity. In US surveillance, rotavirus positive cases were more often white, 62.2 percent vs 57.7 percent, compared with rotavirus negative controls. Rates of rotavirus test positive stools were lower in Hispanic ethnicity were significantly less likely to be nonsecretors, potentially indicating enhanced rotavirus gastroenteritis risk among Hispanic children compared with non-Hispanic children. This is substantiated by pre vaccine studies showing a higher burden of rotavirus among Hispanic or Native American populations, particularly among young age groups.

Mortality and Survival Analysis of the Disease

Annually, 128,500 deaths among children under five are attributed to rotavirus globally. It is estimated that India accounts for one fifth of the global rotavirus attributed deaths. This is about 25,700 deaths per year now.

Country

Key Insights

United States

Rotavirus was the leading cause of acute gastroenteritis in children until the 2006 vaccine introduction. Pre-vaccine it caused about 3 million cases, 55,000-70,000 hospitalizations, and 20-69 deaths annually. Vaccination coverage is high (median 87 percent), and the vaccine remains highly effective, with 78 percent effectiveness against ED visits or hospitalization. Predominant strains include G1P(8), G2P(4), G3P(8), and G12P(8).

Germany

Rotavirus vaccines have been available since 2006, with STKO recommending infant vaccination since 2013. Since then, case numbers have declined, particularly severe cases. However, outbreaks still occur, with 6,399 cases reported in North Rhine-Westphalia in 2025, up from 4,091 the previous year. Rotavirus remains a leading cause of acute gastroenteritis in infants and young infants.

France

Rotavirus causes an estimated 60,000 GP consultations and 20,000 hospitalizations annually in children under 3. It accounts for 30-50% of acutes viral gastroenteritis in infants and young children. Vaccination was recommended for all infants in 2022, with a 2- or 3- dose oral schedule starting at 6 weeks.

Italy

Rotavirus causes approximately 250,000 cases of gastroenteritis annually in children under 5, leading to over 70,000 medical visits and more than 10,000 hospitalizations. Vaccination coverage reached about 70 percent by 2022. Rotavirus remains the most common agent of pediatric viral gastroenteritis, though prevalence has declined post-vaccination (from 32.6 percent to 13.3 percent in one Sicilian study).

Spain

A nationwide population-prevalence estimate for rotavirus infection in Spain was not established from the reviewed 2023-2026 sources. Rotavirus surveillance results should be expressed as laboratory-confirmed cases, positivity among tested patients, or hospitalizations, with the period and age group specified. These indicators are affected by testing and reporting practices and do not capture all infections.

United Kingdom

A nationwide population-prevalence estimate for rotavirus infection in the United Kingdom was not established from the reviewed 2023-2026 sources. UK Health Security Agency surveillance provides seasonal laboratory reports and outbreak monitoring; its 2023-2024 reporting series describes rotavirus activity in England using laboratory and outbreak surveillance systems. These data are useful for assessing recent circulation but do not represent the total number of infections in the population. A prevalence percentage should not be inferred from surveillance counts without an appropriate denominator.

Japan

A reliable nationwide population-prevalence estimate for rotavirus infection in Japan was not established from the reviewed 2023–2026 sources. Japan’s infectious-disease surveillance system publishes rotavirus detections and seasonal trends, including data for the 2023–2024 season. These are surveillance observations rather than population-wide case counts and cannot independently establish national prevalence. A current estimate should specify whether it measures laboratory-confirmed cases, rotavirus positivity among children with gastroenteritis, or hospitalization rates.

India

A reliable nationwide population-prevalence percentage for rotavirus infection in India was not established from the reviewed 2023–2026 sources. However, a 2026 analysis using Global Burden of Disease 2023 estimates attributed approximately 9,387 deaths (95% uncertainty interval: 6,251-14,190) among Indian children younger than five to rotavirus in 2023, indicating a substantial residual burden. This is a modelled mortality estimate, not a prevalence or diagnosed-case count. India’s epidemiological profile should therefore distinguish rotavirus-attributable mortality and disease burden from laboratory-confirmed cases and population prevalence.